

## **BOUSTEAD EXPANDS HEALTHCARE TECHNOLOGY PORTFOLIO WITH MAJORITY STAKE IN SINGAPORE UROLOGY ROBOTICS COMPANY**

**SINGAPORE, 3 July 2026** – Boustead Singapore Limited (“Boustead” or the “Group”), is pleased to announce that Boustead Medical Care Holdings Pte Ltd (“BMCH”) has today, acquired a 60 per cent stake in UroMedTech Pte Ltd (“UroMedTech”) through a S\$6 million equity injection. UroMedTech is a Singapore-based medical technology company pioneering integrated robotic solutions for prostate cancer diagnosis through its UroMaster system, with a research and development roadmap to integrate focal therapy treatment within UroMaster. BMCH, under the Group’s Healthcare Division, is a healthcare technology and services company focused on rehabilitation robotics, digital healthcare and medical innovation.

Founded by a team headed by Dr Wilson Gao, UroMedTech has established itself as an emerging innovator in urology robotics. The company has secured regulatory approvals for UroMaster’s use in prostate cancer diagnosis in multiple markets including Singapore, Malaysia, Australia and other parts of Asia and the technology is currently successfully deployed across seven clinical settings and hospitals in Singapore, Malaysia, Thailand and the Philippines.

Dr Wilson Gao, Founder and Chief Executive Officer of UroMedTech, said, “Joining the Boustead family marks a new chapter for UroMedTech. We founded the company with a vision of transforming the prostate cancer journey from a fragmented process into a seamless, technology-enabled experience for both clinicians and patients. BMCH shares our commitment to healthcare innovation and patient-centered care, and together we hope to accelerate its development and clinical adoption. We have filed for regulatory approvals in the US and the EU, and have sights on obtaining approvals in other global markets within the next few years.”

UroMedTech’s integrated platform addresses longstanding challenges in prostate cancer management by improving diagnostic accuracy, reducing procedural complexity and enabling more personalised treatment pathways. The investment into UroMedTech will allow the Group to expand its healthcare technology portfolio into the rapidly growing field of precision urology and oncology and positions the Group to capitalise on emerging trends in AI-driven technology.

Prostate cancer is among the most prevalent cancers affecting men globally, with more than 1.4 million new cases diagnosed annually, according to [International Agency for Research on Cancer’s GLOBOCAN 2022 estimates](#). UroMedTech’s flagship UroMaster platform currently delivers robotic MRI-ultrasound fusion targeted biopsy, providing clinicians with a precise and streamlined solution for prostate cancer diagnosis. Building on this foundation, the company’s product development roadmap includes AI-assisted pathology and focal therapy treatment capabilities, with the long-term vision of creating a seamless workflow that integrates diagnosis, treatment planning and therapy within a single platform. Through the acquisition, BMCH intends to accelerate the commercialisation of UroMaster, support the development of these next-generation capabilities, and expand UroMedTech’s international presence by leveraging its regional distribution network, which includes public and private clinics and hospitals.

Following completion of the acquisition, UroMedTech will continue to operate under its existing brand while working closely with BMCH to expand research and development, strengthen clinical partnerships and pursue regulatory approvals in key international markets. The acquisition is part of BMCH’s strategy for securing long-term growth prospects through scalable, high-margin medical technology platform with recurring revenue opportunities from consumables, software subscriptions and clinical services.

## *Company Announcement*

---

The above is not expected to have a material impact on the profitability, earnings per share and tangible net asset value per share of the Boustead Group in the financial year ending 31 March 2027.

-- END OF COMPANY ANNOUNCEMENT --

## About Boustead Singapore Limited

Established in 1828, Boustead Singapore Limited (SGX:F9D) is a progressive global Infrastructure-Related Engineering and Technology Group listed on the SGX Mainboard.

As Singapore's oldest continuous business organisation, we focus on the niche engineering and development of key infrastructure to support sustainable shared socio-economic growth. Our strong suite of engineering services under our Energy Engineering Division and Real Estate Solutions Division centres on energy infrastructure and smart, eco-sustainable and future-ready real estate developments.

In addition, we provide technology-driven transformative solutions to improve the quality of life for all walks of life. Our Geospatial Division provides professional services and exclusively distributes Esri ArcGIS technology – the world's leading geographic information system, smart mapping and location analytics enterprise platform – to major markets in the Asia Pacific. The enterprise platform develops digital infrastructure solutions and digital twins, empowering intelligent choices for nations, cities and communities and helps them address complex challenges both locally and globally. Enhanced planning and stewardship of vital infrastructure and resources are essential for ensuring economic resilience, safeguarding the environment and maintaining social accountability. Our Healthcare Division provides innovative medical solutions that address age-related chronic diseases and mobility issues, with a focus on rehabilitative care and sports science in the Asia Pacific.

With a vast global network stretching across Asia, Australia, Europe, Africa and the Americas, we are ready to serve the world. To date, we have an installed project base in 95 countries and territories globally.

Over the years, we have been a recipient of many reputable awards including the prestigious Forbes Asia 200 Best Under A Billion Award. In 2019, we were awarded the Most Transparent Company Award and Sustainability Award (Runner-Up) by the Securities Investors Association (Singapore). Between 2020 to 2023, we also ranked among Singapore's Best Employers, Singapore's Fastest Growing Companies and Asia-Pacific High-Growth Companies. We were also honoured with the Corporate Excellence & Resilience Award at the Singapore Corporate Awards 2021 Special Edition.

Visit us at [www.boustead.sg](http://www.boustead.sg).

## Contact Information

For investor and media enquiries related to Boustead Singapore Limited, please contact:

Mr Dominic Seow  
Senior Manager  
Corporate Marketing & Investor Relations

T +65 6747 0016  
D +65 6709 8111  
E [dominic.seow@boustead.sg](mailto:dominic.seow@boustead.sg)